125 related articles for article (PubMed ID: 3007605)
21. Decreased angiotensin II response but unaltered cardiovascular pressor response to infused norepinephrine after sodium restriction and converting enzyme inhibition.
Mills PJ; Dimsdale JE; Ziegler MG; Nelesen RA; Brown MR
Clin Pharmacol Ther; 1993 Apr; 53(4):450-6. PubMed ID: 8477561
[TBL] [Abstract][Full Text] [Related]
22. Effects of angiotensin II and ACE inhibitors on electrically stimulated noradrenaline release from superfused rat brain slices.
Schacht U
Clin Exp Hypertens A; 1984; 6(10-11):1847-51. PubMed ID: 6099769
[No Abstract] [Full Text] [Related]
23. Influence of ramipril diacid on the peripheral vascular effects of angiotensin I.
Webb DJ; Collier JG
Am J Cardiol; 1987 Apr; 59(10):45D-49D. PubMed ID: 2953225
[TBL] [Abstract][Full Text] [Related]
24. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.
Böhm RO; van Baak MA; Rahn KH
Eur J Clin Pharmacol; 1986; 30(5):541-7. PubMed ID: 3019702
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.
Gohlke P; Schölkens B; Henning R; Urbach H; Unger T
J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S32-6. PubMed ID: 2483426
[TBL] [Abstract][Full Text] [Related]
26. The opposing effects of chronic angiotensin-converting enzyme blockade by captopril on the responses to exogenous angiotensin II and vasopressin vs. norepinephrine in rats.
Spertini F; Brunner HR; Waeber B; Gavras H
Circ Res; 1981 May; 48(5):612-8. PubMed ID: 6260396
[TBL] [Abstract][Full Text] [Related]
27. Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II.
Imai Y; Abe K; Seino M; Haruyama T; Tajima J; Yoshinaga K; Sekino H
Am J Cardiol; 1982 Apr; 49(6):1537-9. PubMed ID: 7041592
[TBL] [Abstract][Full Text] [Related]
28. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
Metzger H; Maier R; Sitter C; Stern HO
Arzneimittelforschung; 1984; 34(10B):1402-6. PubMed ID: 6097265
[TBL] [Abstract][Full Text] [Related]
29. ACE inhibition and pressor responsiveness to norepinephrine in hypertensive patients.
Malini PL; Strocchi E; Valtancoli G; Ambrosioni E
J Clin Pharmacol; 1990 May; 30(5):422-4. PubMed ID: 2161435
[TBL] [Abstract][Full Text] [Related]
30. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failure.
Schölkens BA; Martorana PA; Göbel H; Gehring D
Clin Exp Hypertens A; 1986; 8(6):1033-48. PubMed ID: 3019594
[TBL] [Abstract][Full Text] [Related]
32. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
Unger T; Fleck T; Ganten D; Lang RE; Rettig F
Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
[TBL] [Abstract][Full Text] [Related]
33. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
Karlberg BE; Lindström T; Rosenqvist U; Ohman KP
Am J Cardiol; 1987 Apr; 59(10):104D-109D. PubMed ID: 3034016
[TBL] [Abstract][Full Text] [Related]
34. Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.
Mauersberger H; Witte PU
Lancet; 1985 Mar; 1(8427):517-8. PubMed ID: 2857878
[No Abstract] [Full Text] [Related]
35. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.
Wenting GJ; Blankestijn PJ; Poldermans D; van Geelen J; Derkx FH; Man in't Veld AJ; Schalekamp MA
Am J Cardiol; 1987 Apr; 59(10):92D-97D. PubMed ID: 3034041
[TBL] [Abstract][Full Text] [Related]
36. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
[TBL] [Abstract][Full Text] [Related]
37. Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.
Caspritz G; Alpermann HG; Schleyerbach R
Arzneimittelforschung; 1986 Nov; 36(11):1605-8. PubMed ID: 3028436
[TBL] [Abstract][Full Text] [Related]
38. Influence of ramipril on release of norepinephrine during sympathetic nerve stimulation in isolated rabbit hearts.
Xiang JZ; Schölkens BA
Zhongguo Yao Li Xue Bao; 1988 Jul; 9(4):320-2. PubMed ID: 2973724
[No Abstract] [Full Text] [Related]
39. Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man.
Erman A; Winkler J; Chen-Gal B; Rabinov M; Zelykovski A; Tadjer S; Shmueli J; Levi E; Akbary A; Rosenfeld JB
J Hypertens; 1991 Nov; 9(11):1057-62. PubMed ID: 1661764
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers.
Thuillez C; Richer C; Giudicelli JF
Am J Cardiol; 1987 Apr; 59(10):38D-44D. PubMed ID: 3034032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
